1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 31-40 of 41 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2012Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibWhite, D.; Radich, J.; Soverini, S.; Saunders, V.; Frede, A.; Dang, P.; Cilloni, D.; Lin, P.; Mongay, L.; Woodman, R.; Manley, P.; Slader, C.; Kim, D.; Pane, F.; Martinelli, G.; Saglio, G.; Hughes, T.
2013Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Eadie, L.; Saunders, V.; Hughes, T.; White, D.
2011Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathwaysTang, C.; Schafranek, L.; Watkins, D.; Parker, W.; Moore, S.; Prime, J.; White, D.; Hughes, T.
2016ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell linesEadie, L.; Hughes, T.; White, D.; Eaves, C.
2015Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemiaSchafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; Leclercq, T.; Hughes, T.; White, D.
2017Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesionsSadras, T.; Heatley, S.; Kok, C.; Dang, P.; Galbraith, K.; McClure, B.; Muskovic, W.; Venn, N.; Moore, S.; Osborn, M.; Revesz, T.; Moore, A.; Hughes, T.; Yeung, D.; Sutton, R.; White, D.
2017A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOHSadras, T.; Heatley, S.; Kok, C.; McClure, B.; Yeung, D.; Hughes, T.; Sutton, R.; Ziegler, D.; White, D.
2018Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expressionMcClure, B.; Heatley, S.; Kok, C.; Sadras, T.; An, J.; Hughes, T.; Lock, R.; Yeung, D.; Sutton, R.; White, D.
2017Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cellsWang, J.; Lu, L.; Kok, C.; Saunders, V.; Goyne, J.; Dang, P.; Leclercq, T.; Hughes, T.; White, D.
2017CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patientsBarratt, D.; Cox, H.; Menelaou, A.; Yeung, D.; White, D.; Hughes, T.; Somogyi, A.

Discover